Precision Pathology Laboratory Services

07/22/2025

We’re excited to announce that Canada has awarded a new patent protecting the technology behind CyPath® Lung, our noninvasive, early-stage lung cancer diagnostic.
This patent expands our global IP portfolio and supports our mission to detect lung cancer early.
CyPath® Lung has demonstrated:
92% sensitivity
87% specificity
88% accuracy
Another step forward in bringing life-saving innovation to patients worldwide.
Read the press release here: https://bit.ly/CanadaPatent

New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, TX — July 22, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s ...

07/17/2025

CyPath® Lung provides physicians with timely, actionable information for patients at risk of lung cancer. Early detection is critical and speedy results save lives.
Learn more about how CyPath® Lung supports confident clinical decisions through noninvasive, early-stage lung cancer detection.

See how Dr. Nadarajah uses CyPath® Lung: https://bit.ly/DrNadarajah

07/16/2025

bioAffinity Technologies Receives Patent Allowance in China for CyPath® Lung
We’re proud to announce a new Chinese patent protecting our noninvasive lung cancer diagnostic, CyPath® Lung which is a major step in expanding our international IP portfolio.

With over 300 million smokers and the highest rate of lung cancer globally, China is a critical market for early detection. This patent supports our mission to bring life-saving diagnostics to those who need them most.
“Securing this IP positions us well for future opportunities in one of the world’s largest and most underserved healthcare markets.”
Maria Zannes, President & CEO

CyPath® Lung has shown 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.
Read the press release: https://bit.ly/3IuVgS3

One third of world’s smokers live in China, which has highest rate of lung cancer SAN ANTONIO, TX — July 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially avail...

07/10/2025

Improving patient care starts with rapid answers.
CyPath® Lung provides actionable lung cancer detection results in just 3 days, enabling earlier intervention and greater peace of mind.

Nurse Practitioner Israel Garcia shares how this test is making a difference in clinical practice.
Check it out: https://lnkd.in/gKmimtCP

07/10/2025

“CyPath® Lung gave us the confidence to intervene surgically when everything else pointed to watchful waiting,” said Dr. Gordon Downie, recalling a recent case where Stage 1A adenocarcinoma was successfully detected.
Thanks to early detection, the patient received timely care—when it mattered most.
CyPath® Lung is bringing clarity to diagnosis and helping save lives.

Read the press release: https://bit.ly/3TsciT5

07/04/2025

Happy 4th of July!
Today, we celebrate the freedom to innovate and the power of science to improve lives. Here's to independence and a healthier future for all.

07/03/2025

When the Data Speaks, Investors Listen

CyPath® Lung detected lung cancer in high-risk patients with 92% sensitivity and 87% specificity for lung nodules

07/02/2025

Lung cancer remains a leading cause of cancer-related deaths in the U.S., accounting for nearly 1 in 5 such fatalities. The solution? Early detection and diagnosis. CyPath® Lung has proven 92% sensitivity and 87% specificity with pulmonary nodules less than 20mm.

See what Dr. Nadarajah had to say about the benefits of adding CyPath® Lung to his practice: https://bit.ly/DrNadarajah

06/27/2025

Congrats to Dr. David Elzi, our VP of Product Development, for presenting at the RNA Therapeutics Conference this week. Dave shared his research on using siRNAs to suppress the expression of two specific proteins on the cell membrane to selectively kill cancer cells without harm to healthy cells.
The double knockdown of CD320 and LRP2 holds substantial promise for targeted RNA-based cancer therapeutics and underscores our commitment to advancing precision oncology through innovative science.

06/24/2025

Early detection saved Linda’s life.
She had no symptoms, but a routine low-dose CT scan found early-stage lung cancer. Thanks to proactive screening, she avoided chemo and is now cancer-free.
Stories like Linda’s highlight the power of preventive care.
At CyPath® Lung, we support physicians with a noninvasive test that helps assess lung nodules—quickly and accurately.
• Results in 3 days
• Noninvasive
• Informs next steps

Read her story: https://bit.ly/CTsaves

Despite having no symptoms, Linda’s commitment to preventive care led to a life-saving lung cancer diagnosis. Learn why early screening matters.

06/20/2025

Early, accurate diagnosis can change everything, especially when it comes to lung cancer. CyPath® Lung offers a noninvasive way to help physicians identify malignant lung nodules, with results available in just 3 days.
Dr. Nadarajah is one of the many physicians using CyPath® Lung to enhance patient care and make more informed decisions.

Learn more about how CyPath® Lung is shaping the future of lung cancer diagnostics: https://bit.ly/DrNadarajah

06/19/2025

Juneteenth marks the day in 1865 when the last enslaved people in the U.S. learned of their freedom. This important day reminds us of the profound impact of historical injustices on health and society.
We are committed to contributing to a future where advanced diagnostics and care are accessible to all, helping to close health disparity gaps and foster healthier communities.
Learn more about Juneteenth and its significance today.